Description

ResMed Unlocks A Bigger Sleep-Health Ecosystem With OURA And Noctrix!

ResMed, a global leader in connected health technology primarily focused on sleep and respiratory care, reported its fourth quarter and full fiscal year 2026 results, highlighting 9% and 10% headline revenue growth respectively, with 8% growth on a constant currency basis. Non-GAAP earnings per share increased 16% in the quarter and 17% for the year, driven by operational efficiencies and margin expansion despite inflationary pressures. The company generated $1.6 billion in free cash flow for fiscal 2026, supporting substantial shareholder returns through over $1 billion in combined share repurchases and dividends, with a notable 72% year-over-year increase in capital returned. Operational highlights include continued progress in supply chain efficiency, leading to a year-over-year gross margin expansion of 90 basis points in Q4, albeit with a sequential margin decline of 50 basis points due principally to inflation in electronic components and freight costs, as well as foreign exchange headwinds.